230 related articles for article (PubMed ID: 24462475)
1. The role of CD81 for plasma cell dyscrasias.
Binder M; Bacher U
Leuk Res; 2014 Mar; 38(3):292-3. PubMed ID: 24462475
[No Abstract] [Full Text] [Related]
2. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.
Tembhare PR; Yuan CM; Venzon D; Braylan R; Korde N; Manasanch E; Zuchlinsky D; Calvo K; Kurlander R; Bhutani M; Tageja N; Maric I; Mulquin M; Roschewski M; Kwok M; Liewehr D; Landgren O; Stetler-Stevenson M
Leuk Res; 2014 Mar; 38(3):371-6. PubMed ID: 24462038
[TBL] [Abstract][Full Text] [Related]
4. [Monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma].
Schleiffenbaum BE
Praxis (Bern 1994); 2012 Nov; 101(24):1521-9; quiz 1530-1. PubMed ID: 23184544
[No Abstract] [Full Text] [Related]
5. Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance.
Jerez A; Ortuño FJ; Osma Mdel M; Español I; González AD; Roldán V; de Arriba F; Vicente V
Ann Med; 2009; 41(7):547-58. PubMed ID: 19634064
[TBL] [Abstract][Full Text] [Related]
6. Activity of aldehyde dehydrogenase in B-cell and plasma cell subsets of monoclonal gammopathy patients and healthy donors.
Všianská P; Bezděková R; Kryukov F; Almáši M; Pour L; Penka M; Hájek R; Říhová L
Eur J Haematol; 2017 Jan; 98(1):19-25. PubMed ID: 27199264
[TBL] [Abstract][Full Text] [Related]
7. Bone-marrow plasmocytosis--an immunohistological study.
Eckert F; Schmid L; Kradolfer D; Schmid U
Blut; 1986 Jul; 53(1):11-9. PubMed ID: 3719110
[TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma.
Kumar SK; Rajkumar V; Kyle RA; van Duin M; Sonneveld P; Mateos MV; Gay F; Anderson KC
Nat Rev Dis Primers; 2017 Jul; 3():17046. PubMed ID: 28726797
[TBL] [Abstract][Full Text] [Related]
9. Advances in the diagnosis and management of myeloma.
Greipp PR
Semin Hematol; 1992 Jul; 29(3 Suppl 2):24-45. PubMed ID: 1509293
[No Abstract] [Full Text] [Related]
10. Multiple myeloma arising from monoclonal gammopathy of undetermined significance in a patient with Gaucher's disease.
Brady K; Corash L; Bhargava V
Arch Pathol Lab Med; 1997 Oct; 121(10):1108-11. PubMed ID: 9341594
[TBL] [Abstract][Full Text] [Related]
11. [Management in paraproteinemia].
Sonneveld P; Löwenberg B
Ned Tijdschr Geneeskd; 1992 Feb; 136(8):384-5. PubMed ID: 1538819
[No Abstract] [Full Text] [Related]
12. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
13. The value of the bone marrow plasma cell cytoplasmic light chain ratio in differentiating between multiple myeloma and monoclonal gammopathy of undetermined significance.
Majumdar G; Grace RJ; Singh AK; Slater NG
Leuk Lymphoma; 1992 Dec; 8(6):491-3. PubMed ID: 1297481
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal gammopathy of undetermined significance: a new proposal of workup.
Mangiacavalli S; Cocito F; Pochintesta L; Pascutto C; Ferretti V; Varettoni M; Zappasodi P; Pompa A; Landini B; Cazzola M; Corso A
Eur J Haematol; 2013 Oct; 91(4):356-60. PubMed ID: 23859528
[TBL] [Abstract][Full Text] [Related]
15. Necrobiotic xanthogranuloma in IgG-κ multiple myeloma.
Giacalone S; Genovese G; Benzecry V; Berti E; Cusini M
Br J Haematol; 2021 Apr; 193(2):211. PubMed ID: 33529369
[No Abstract] [Full Text] [Related]
16. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.
Sezer O; Heider U; Zavrski I; Possinger K
Haematologica; 2001 Aug; 86(8):837-43. PubMed ID: 11522540
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
18. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
Paiva B; Vídriales MB; Rosiñol L; Martínez-López J; Mateos MV; Ocio EM; Montalbán MÁ; Cordón L; Gutiérrez NC; Corchete L; Oriol A; Terol MJ; Echeveste MA; De Paz R; De Arriba F; Palomera L; de la Rubia J; Díaz-Mediavilla J; Granell M; Gorosquieta A; Alegre A; Orfao A; Lahuerta JJ; Bladé J; San Miguel JF;
Leukemia; 2013 Oct; 27(10):2056-61. PubMed ID: 23743858
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of multiple myeloma and related disorders.
Kyle RA
Prog Hematol; 1986; 14():257-82. PubMed ID: 2418463
[No Abstract] [Full Text] [Related]
20. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
